Abstract Efficient treatment of ocular diseases can be achieved thanks to the proper use of ophthalmic formulations based on emerging pharmaceutical approaches. Among them, microtechnology and nanotechnology strategies are of great interest in the development of novel drug delivery systems to be used for ocular therapy. The location of the target site in the eye as well as the ophthalmic disease will determine the route of administration (topical, intraocular, periocular, and suprachoroidal administration) and the most adequate device. In this review, we discuss the use of colloidal pharmaceutical systems (nanoparticles, liposomes, niosomes, dendrimers, and microemulsions), microparticles (microcapsules and microspheres), and hybrid systems (combination of different strategies) in the treatment of ophthalmic diseases. Emphasis has been placed in the therapeutic significance of each drug delivery system for clinical translation.
Introduction
The eye is divided in anterior segment (from cornea to lens, bath by aqueous humor) and posterior segment (from lens to the eye fundus, filled by the vitreous) (Fig. 1) . Ocular drug delivery is one of the most challenging fields of pharmaceutical research. As the eye has several defense mechanisms to prevent the entrance of exogenous substances, the drug must overcome different protecting barriers to achieve the target tissue. In this context, the active substance must overcome static barriers (cornea, sclera, and retina including blood aqueous and blood-retinal barriers) and/or dynamic barriers (choroidal and conjunctival blood flow, lymphatic clearance, and tear dilution) that are protecting the eye, to reach the target site.
Topical administration is the preferred route to reach the anterior segment of the eye or to treat diseases affecting the ocular surface. However, it has been estimated that only a low percentage (around 5 %) of the administered drug is able to reach the aqueous humor or get access inside the eye when conventional eye drops are used. This poor ocular bioavailability is due to different events such as the short residence time of formulations on the ocular surface, the drainage of the solution, tear turnover, dilution by lacrimation, the low corneal permeability, or the conjunctival absorption of the drug and scleral transport [1] . Several therapeutic approaches (mainly nanosystems) have been developed to increase ocular drug bioavailability. After topical administration, they are directed toward the increase of the retention time of drugs on the ocular surface and, in some cases, to enhance the corneal transport, reducing the number of applications per day and increasing the patients' compliance.
When the target tissue is located in the posterior segment of the eye, mainly one or more than one type of retinal neurons (Fig. 2a) , the use of topical or systemic administrations is I. Bravo-Osuna and V. Andrés-Guerrero Both authors have collaborated in the same extent ineffective because of the above mentioned ocular barriers. Subsequently, for the treatment of these pathologies, intravitreal injection is preferred. In those cases in which the drug is able to cross the different tissues to reach the back of the eye, a less invasive route (periocular injection) can be also considered. The main disadvantage of these administrations is the need of repeated injections to achieve therapeutic drug levels for prolonged periods of time, which is generally necessary to treat chronic posterior segment pathologies. In that sense, drug delivery systems may address the risk of side effects associated with repeated injections, as they are able to release the drug for long periods of time. At this level, nanosystems and microsystems are useful tools to protect the active substance from the external environment and/or to target the drug to the ocular tissues.
In the past decades, microsystems and nanosystems (liposomes, nanoparticles, niosomes, microemulsions, and more recently dendrimers) have emerged as interesting drug delivery alternatives in ophthalmology. However, ophthalmic pharmaceutical formulations must fulfill some restricted specifications different to those designed for other targets, such as sterility, compatibility, and tolerability. This review is dedicated to describe the most promising research performed in this field. The information has been classified according to the ocular administration route selected (topical, intraocular, and periocular). A novel approach currently under investigation is the use of the suprachoroidal space located between sclera and choroid as a reservoir for active substances (Fig. 1 ).
Topical administration
As cited previously, the administration of drugs on the ocular surface by topical instillation of eye drops is the most common drug delivery route for the treatment of ocular pathologies affecting the ocular surface or when the drug has to reach the anterior segment. However, having clear advantages such as easy self-application, the main drawback of this route is the rapid clearance of the drug from the ocular surface, due to nasolacrimal drainage and tear dynamics and the reduced permeability across the ocular tissues. Once the drug reaches the ocular surface, it is diluted in the precorneal film ( Fig. 2b) and subsequently crosses the cornea (Fig. 2c ) to reach the aqueous humor. This fact reduces the bioavailability of drugs, limiting the use of the topical route to the treatment of anterior segment diseases.
Several technological strategies to increase the bioavailability of drugs by topical administration are under study. These strategies are based on the use of systems able to stay for longer periods of time on the ocular surface due to interactions with ocular mucins (gel-forming and transmembrane mucins mainly), which are the major components on the preocular tear film (Fig. 2b) . In this sense, the use of 
Microparticles
Microparticles are solid drug carriers (1-1000 μm) capable of providing sustained and controlled release of loaded active agents. According to their structure, microparticles can receive the name of microcapsules (reservoir structure) and microspheres (matrix structure) (Fig. 3) .
The use of microparticles for topical therapies is not very common. One of the main reasons is their short contact time on the ocular surface. It is also important to note that the size of microparticles has to be controlled to be less than 10 μm to avoid possible eye irritation [2, 3] .
Some authors have studied the use of polymeric biodegradable microparticles for ophthalmic topical administration. Addo et al. showed that the use of tetracaine-loaded microparticles (4 μm bovine serum albumin-chitosan microparticles, prepared by the spray-drying method) increased the anesthetic effect of the drug up to 4-fold in rabbits, in comparison with a commercialized ophthalmic solution [4] . Other authors have examined the hypothesis that mucoadhesive microparticles may offer a means for slow drug release from the particles that remain adherent to the ocular surface for an extended period of time. In that sense, Sensoy et al. demonstrated the utility of mucoadhesive polymers for the preparation of bioadhesive microspheres loaded with sulfacetamide (2 μm polycarbophil microspheres, prepared by the spraydrying method) for the treatment of keratitis in rabbits [5] . Choy et al. observed that the use of a mucoadhesion promoter such as polyethyleneglycol (PEG) increased the microparticles' retention time (nile red-labeled polylactic-coglycolic-PEG microparticles, <10 μm) up to 1 h on the ocular surface of rabbits [6, 7] . Park et al. also used PEG as additive with poly(lactic-co-glycolic acid) (PLGA) microspheres loaded with brimonidine. The mucoadhesive microparticles Ions and mucins (soluble and gel-forming) are dissolved in the aqueous layer. The transmembrane ocular mucin layer connects the precorneal tear film with the corneal epithelium. c Structure of the cornea. The stratified corneal epithelium is followed by a predominantly aqueous stroma. The monolayer corneal endothelium is in contact with the aqueous humor. The main barrier for active substances entrance is the stratified epithelium that can be crossed by the intracellular or paracellular pathway increased drug bioavailability of the hypotensive agent more than 2-fold compared to the marketed brimonidine formulation [8] .
Nanoparticles
Nanoparticles are solid, submicron-sized drug carriers with diameters ranging from 1 to 1000 nm. Depending on their structure, they can be also classified into nanospheres and nanocapsules (Fig. 3 ). Because of their particle size, nanoparticulate systems offer the possibility to enhance the delivery and transport of drugs across ocular tissues. Nowadays, it is possible to find studies in which drugloaded nanoparticles prepared with biodegradable materials (such as poly(lactic) acid (PLA), PLGA, chitosan, or albumin) demonstrate promising results.
Vega et al. showed that the topical administration of flurbiprofen-loaded nanoparticles (232-277 nm PLGA nanoparticles, prepared by the nanoprecipitation method) presented higher anti-inflammatory effect than a solution of sodium arachidonate, used as a reference, after topical instillation in rabbit eyes [9] . De Campos et al. studied cyclosporine Aloaded nanoparticles for topical administration (300 nm chitosan nanoparticles, developed by ionic gelation technique). Chitosan is able to interact with ocular mucins and also open tight junctions of the epithelial cells, promoting the transcorneal flux. The system created improved the interaction of the drug with corneal and conjunctival tissues, finding therapeutic levels of cyclosporine at least during 24 or 48 h postadministration in ocular surface tissues (conjunctiva and cornea, respectively) [10] . Chaiyasan et al. developed chitosandextran sulfate nanoparticles with a mean size of around 400 nm, as a topical ocular delivery system with lutein as a model drug (entrapment efficiency in the range of 60-76 %). The positively charged nanoparticles (+46 mV) exhibited mucoadhesive properties measured by electrostatic interactions when examined in vitro using a membrane coated with mucin to simulate the ocular surface, being considered Fig. 3 Structure of different microsystems and nanosystems currently under development for the treatment of ocular diseases: microparticles and nanoparticles (while in microspheres and nanospheres the active substance is in intimate contact with the polymer forming a matrix system, in microcapsules and nanocapsules it is confined in a reservoir core surrounded by the polymer); liposomes (hydrophobic active substances can be loaded in the apolar lipid bilayer while hydrophilic active substances can be included inside the vesicle or adsorbed on the surface); microemulsions (can load hydrophobic active substances in the oil phase); niosomes (hydrophobic active substances can be located in the surfactant bilayer and hydrophilic compounds inside the vesicle or adsorbed on the surface); and dendrimers (hyper-branched polymers that can interact with active substances inside their structure mainly by hydrophobic interactions, or on their surface both by covalent and noncovalent binding) suitable for topical ophthalmic drug delivery [11] . In a different study, brimonidine-loaded nanoparticles were prepared by the ionic gelation technique in order to improve the bioavailability and to prolong the residence time of the formulation in the eye. Nanoparticles, with a mean particle size rage of about 270-370 nm (polydispersity index <0.5), showed an entrapment efficiency of the drug from 36 to 49 %. In vivo studies showed a sustained effect of the formulation in comparison with conventional eye drops [12] .
Liu et al. [13] demonstrated that the ocular delivery of baicalin (an anti-inflammatory and analgesic agent) could be enhanced by the use of solid lipid nanoparticles (91 nm, emulsification/ultrasonication method). These nanoparticles were able to enhance the corneal penetration of the drug in permeation studies performed in excised rabbit corneas. A significantly higher bioavailability of tobramycin was shown when 100-nm drug-loaded solid lipid nanoparticles were administered on the ocular surface in rabbit eyes. Data indicated an increase of a 1.5-fold C max , 8-fold t max , and 4-fold AUC with respect to the same dose of a tobramycin aqueous solution [14] . A higher therapeutic efficacy and a more prolonged effect were observed for methazolamide-loaded solid lipid nanoparticles when compared with a commercial formulation of the antiglaucoma active agent [15] .
Hao et al. [16] prepared solid lipid nanoparticles within the colloidal range, dispersed in poloxamer-based hydrogels with thermosensitive in situ gelling properties (27.5 % poloxamer 407 and 3.55 % poloxamer 188). In vitro corneal penetration revealed a nearly steady sustained drug release. Toxicity tests in the hen's egg test-chorioallantoic membrane showed no irritation, suggesting these systems as potential vehicles for ocular application. Wang et al. prepared diblock elastin-like polypeptide-based nanoparticles with a multivalent presentation of lacritin at the surface (20-30-nm micelles at physiologically relevant temperatures) [17] . Thermo-responsive nanoparticles exhibited mitogenic activity in SV40-transduced human corneal epithelial cells. The in vivo efficacy was explored in wounds on the ocular surface of female nonobese diabetic mice. Two doses of nanoparticles within 12 h after surgery produced significantly faster wound healing than controls. Histology analysis revealed that, after the treatment, no significant corneal inflammation was observed and the reconstituted ocular surface appeared as smooth as preprocedure following 24 h. This report provided the first in vivo verification of lacritin's wound healing potential and can be further applied to rationally bioengineer other peptide therapeutics into self-assembling nanoparticles for treating visual impairments.
Kao et al. prepared a long-lasting pilocarpine-loaded chitosan/carbopol nanoparticle ophthalmic formulation that showed a slower release profile and the most significant long-lasting decrease in the pupil diameters of the rabbits, in comparison with those obtained with other systems such as a pilocarpine solution, a gel, and liposomes [18] . The bioadhesive polymer hyaluronic acid has also been combined with dorzolamide-and timolol-loaded nanoparticles. This combination was very efficient in reducing intraocular pressure in rabbits in comparison with the same dose of a conventional solution of both hypotensive drugs [19] .
The in vivo efficacy of cyclosporine A was also enhanced with the use of these systems [20] . Cationic nanoparticles were also employed to enhance the bioavailability of drugs, applied by topical administration, through electrostatic interactions between the negatively charged ocular surfaces and the positively charged formulation. According to this strategy, Başaran et al. [21] incorporated cyclosporine A into three different types of cationic chitosan nanoparticles. Authors employed low, medium, and high molecular weight chitosan 200 -800, and 800-2000 cPs) to prepare nanoparticles following the spray-drying method (sizes between 318 and 433 nm). Medium molecular weight chitosan nanoparticles showed a more uniform release pattern and were used for the in vivo studies. A volume of 0.5 mL of dispersed nanoparticles (cyclosporine A content 10.58 ± 0.25 or 19.20 ± 0.33 %) was applied in sheep eyes. Then, samples of aqueous humor and vitreous were collected at different time intervals for cyclosporine A quantification. Results showed a prolonged drug release from chitosan-based nanoparticles even after 72 h with levels of 41.00 ± 0.90 and 36.70 ± 0.30 ng/mL in aqueous humor and vitreous samples, respectively.
Liposomes
Liposomes are spherical vesicles composed of an aqueous core enclosed by concentric phospholipid bilayers (Fig. 3) . The size of liposomes ranges from 10 nm to 10 μm. According to their size and the number of lipid bilayers, liposomes are classified into small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles, if more than one bilayer is present.
As well as nanoparticles, liposomal formulations have shown to increase drug residence time and to enhance drug permeation through corneal tissues, due to their size and surface properties. Positively charged liposomes, composed by cationic lipids such as dioleoyl-3-trimethyleammonium propane chloride (DOTAP) or stearylamine (SA), are able to interact with the anionic mucins present on the ocular surface (Fig. 3) , allowing the formation of a completely coated layer, increasing the contact time of the formulation and, subsequently, the drug bioavailability [22] .
Schaeffer et al. reported a 4-fold increase of penicillin G bioavailability with the use of drug-loaded liposomes composed by phosphatidilcholine (PC), cholesterol (Cht), and SA prepared according to the thin-film hydration method, in comparison with the equivalent concentration of free drug [23] . Law et al. showed an increased residence time of acyclovir-loaded liposomes with the same components that promoted an enhanced bioavailability of the drug, in comparison with anionic liposomes, which were drained fast because they were not able to provide an electrostatic interaction with the ocular surface [24] . Also, Saettone et al. compared a positively charged liposomal acyclovir formulation (PC, Cht, and SA, thin film hydration method) with a commercialized ointment. Liposomes increased the acyclovir concentration in the aqueous humor of rabbits when compared with the ointment at the same drug concentration [25] . Acetazolamide-and pilocarpine-loaded liposomes have also been investigated for the treatment of ocular hypertension, promoting a more pronounced and sustained reduction in intraocular pressure than conventional hypotensive solutions [26] . Li et al. investigated the potential of liposomes to enhance the local antiglaucomatous effect of brinzolamide [27] . In vitro release studies of brinzolamide-loaded liposomes (84.33 ± 2.02 nm) displayed a biphasic release pattern with an initial burst release, followed by a second sustained release period. In Franztype diffusion cells, corneal permeability resulted in a 6.2-fold increase in comparison with the commercially available formulation. In vivo studies in rabbits showed a more sustained and effective intraocular pressure reduction (5-10 mmHg) for drug-loaded liposomes. The novel formulation had an onset of less than 30 min, achieved a maximum intraocular pressure (IOP) reduction of 41.1 % at 1 h, and sustained an effective IOP reduction until 12 h, while the reference formulation quickly reached its peak effect (34.5 % IOP reduction) at 1 h and failed to be effective at 12 h. Chetoni et al. evaluated the in vitro and in vivo performance of a topical controlled release liposomal formulation containing distamycin A, for the treatment of acyclovir-resistant Herpes simplex virus keratitis [28] . The bioavailability of the drug in the tear fluid and the uptake into the cornea were increased after instillation of liposomes in rabbits, being less cytotoxic than distamycin A alone in rabbit corneal epithelial cells. Distamycin concentration in cornea reached IC50 values against HSV, without any sign of transcorneal permeation of the drug.
Several studies have shown that hybrid systems (liposomes combined with hydrogels) can increase the residence time of the formulations, thus prolonging the drug release rate [29] . Budai et al. encapsulated ciprofloxacin in multillamelar vesicles that were suspended in different polymeric solutions forming hydrogels, such as polyvinyl alcohol 0.14 % or polymethacrylic acid 0.1 %. The release half-time of ciprofloxacin was increased from 72 min (ciprofloxacin hydrogels without liposomes) to 212 and 644 min when lecithin or α-ldipalmithoyl-phosphatidylcholine lipids were used to prepare the vesicles, respectively [30] . Liposome coating has been demonstrated to increase the release rate of ciprofloxatin up to 10 h (75 % of the dose) using 1.5 % Carbopol® 940 [31] [32] [33] . Additionally, authors observed that the transcorneal permeation of ciprofloxacin was augmented five times with the use of carbopol-covered liposomes, in comparison with uncovered liposomes (3-fold increment) or a ciprofloxacin solution used as a reference [34] . The use of chitosan to form hydrogels to cover drug-loaded liposomes has also showed promising results. Hosny et al. [35] prepared oxoflacin-loaded liposomes dispersed in a thermosensitive gel composed by chitosan and β-glycerophosphate salt (1.8 and 3.8 % w/v, respectively). The presence of the hydrogel increased the amount of drug permeated through the cornea 7-fold, in comparison to the drug aqueous solution at the same concentration. A different interesting technological strategy to achieve higher concentrations of the therapeutic agent in ocular tissues involves the dispersion of drug-loaded liposomes in collagen shields. Pleyer et al. employed this strategy in rabbit eyes. As expected, they found that cyclosporine levels in cornea, sclera, aqueous humor, and vitreous were significantly higher in these animals, in comparison with conventional cyclosporine eye drops [36] . Also, the combination of liposomes and bioadhesive polymers such as carboxymethyl cellulose or hyaluronic acid increased the hypotensive effect of a melatonin analog 5-MCA-NAT (maximum intraocular pressure reduction of 36.72±2.77 and 39.13±2.21 %, respectively) in rabbit eyes compared to other liposomes formulated without polymers (29.44±2.40 %). This hybrid formulation was able to increase the bioavailability of the therapeutic agent (the effect lasted more than 8 h), being soft with the ocular surface. As the novel formulation simulates tear film composition, it might relieve symptoms of secondary diseases affecting the ocular surface derived from the chronic use of antiglaucoma topical medications [37] [38] [39] [40] . In a different approach, Dong et al. designed and prepared ibuprofen-loaded liposomes coated by regenerated silk fibroins, which are novel adhesive excipients with different dissolving times [41] . No detectable toxicity was observed in cells after 12 h of exposure to silk fibroins. The novel liposomes showed sustained release and in vitro corneal permeation of ibuprofen as compared to a drug solution and liposomes without silk fibroins.
Microemulsions
Microemulsions are pharmaceutical systems composed of an oily phase, an aqueous phase, and a combination of surfactant and co-surfactant at appropriate ratios to stabilize the system (Fig. 3) . Microemulsions possess optimal characteristics to be administered by topical route. Depending on their charge and viscosity, the retention time onto the ocular surface can be increased allowing the delivery and permeation of drugs across the ocular surface.
Klang et al. demonstrated that positively charged microemulsions were able to enhance drug corneal penetration, achieving higher concentrations of drug (indomethacin) in aqueous humor and sclera-retina in comparison to negatively charged microemulsions, due to the electrostatic effect between the cationic formulation and the anionic cornea.
Moreover, the positively charged emulsion (composed by poloxamer, stearylamine, lipoid 80, and α-tocopherol) exhibited higher ocular bioavailability and sclera-retina drug levels than the negatively charged emulsion. The ocular tolerance study in rabbit eyes indicated that eight consecutive hourly instillations per day of this formulation were well tolerated, since no toxic or inflammatory response to the ocular surface was detected during the 5 days of the study [42] . The use of bioadhesive polymers in the aqueous phase of the microemulsions has demonstrated to enhance the drug bioavailability as well. Chauhan et al. developed timolol microemulsions in 2-hydroxyethyl methacrylate (HEMA) to extend the release rate of the drug [43] . In the study, gels that had timolol-loaded microemulsions exhibited a fast release in PBS and in saline due to higher solubility of timolol in these solutions compared to that in water (1.5 h versus 25 days). While 100 % of the drug had diffused in water, only 55 % was released in PBS. Although due to the release rate results these systems have limited utility for ophthalmic drug delivery of hypotensive drugs, the drug loading of timolol was very high, so it must be possible to find applications for delivery of other type of molecules to the eye. Phase-transition microemulsions have also been studied for ophthalmic drug delivery purposes. In these microemulsions, there is a phase change after their instillation that produces a viscosity increment and a flow rheological change (from Newtonian to pseudoplastic), increasing the ocular residence time of formulations on the ocular surface [44] [45] [46] [47] .
Niosomes
Niosomes are non-ionic surfactant vesicular systems formed from the self-assembly of non-ionic amphiphilic compounds in aqueous media, resulting in bilayer vesicles of 10-0.5 μm in size (Fig. 3) . They have gained popularity in ocular drug delivery because they can provide prolonged duration of action at the corneal surface and increase the ocular bioavailability of ophthalmic therapeutics.
The use of these systems has shown promising results for the treatment of ocular hypertension associated to glaucoma. Aggarwal et al. reported that acetazolamide-loaded cationic niosomes provided good entrapment efficiency and corneal permeability, being effective for the reduction of intraocular pressure in experimental animals. However, positively charged niosomes, composed of sorbitan ester, cholesterol, and SA, resulted toxic for corneal cells. In order to reduce corneal toxicity of niosomes, a bioadhesive niosomal formulation of acetazolamide was also prepared by coating niosomes with Carbopol®. The bioadhesive formulation was less toxic than non-coated vesicles and showed a 2-fold increment in the duration of action in comparison with a commercial formulation [48] . In a different study, authors observed that the niosomal formulation coated with 0.5 % w/v chitosan and containing a 0.25 w/v solution of timolol maleate extended the release of the drug in vitro up to 10 h. Similarly, a longer prolonged effect was observed when chitosan-coated formulations where instilled on rabbit eyes, in comparison to the administration of a conventional hypotensive solution (8 and 2 h, respectively) [49] . Abdelkader et al. developed naltrexone hydrochloride-loaded niosomes and tested the incorporation of different additives to the formulation, to demonstrate that these compounds can influence the entrapment efficacy and also the size and shape of niosomes [50] . Ex vivo transcorneal permeation studies conducted using excised cow corneas showed that niosomes were capable of controlling drug permeation and enhancing its corneal permeability. These formulations resulted practically nonirritant [51] . The same authors observed that niosomal preparations were able to protect the encapsulated drug from the photo-induced oxidation up to 3-fold in comparison to free naltrexone solutions [52] .
Li et al. developed proniosome-derived niosomes for topical ophthalmic delivery of tacrolimus [53] . Freshly excised rabbit corneas were employed to analyze the in vitro permeation of tacrolimus from the vesicles and the drug retention in the cornea. Results showed a significant increase in tacrolimus permeation as compared with commercial ointments. The in vivo ocular irritation test of 0.1 % tacrolimus-loaded niosomes showed no irritation and good biocompatibility with cornea after 21 consecutive days of instillations (four times/ day). The in vivo antiallograft rejection assessment was performed in a rat corneal xenotransplantation model. The results showed that tacrolimus-loaded niosomes delayed the occurrence of corneal allograft rejection and significantly prolonged the median survival time of corneal allografts, in comparison to cyclosporine eye drops, drug-free niosomes, or untreated eyes. Abu et al. reported the preparation and characterization of an ocular niosomal/hydrogel formulation containing 0.5 % atenolol for the treatment of ocular hypertension associated to glaucoma. Niosomes were prepared with span 60 and cholesterol at different molar ratios. The size of niosomal formulations ranged from 56.5 to 155.3 nm and showed a high retention of atenolol inside vesicles up to a period of 3 months at 4°C (83.1 ± 2.3 %). Examination of rabbit eyes did not show irritation signs. Atenolol niosome/ carbopol gel showed slower and sustained in vitro release of atenolol in comparison to the rest of formulations and a maximum IOP reduction of 49.80 % after 5.33 h of drug administration. The effect was sustained and prolonged for 8 h [54] .
Dendrimers
The term Bdendrimer^arises from the Greek Dendron, meaning Btree,^and meros, meaning Bpart.^It graphically describes the structure of this class of synthetic macromolecules that have highly branched, three-dimensional features that resemble the architecture of a tree (Fig. 3) . Despite their large molecular size (5000-500,000 g/mol), they are structurally welldefined and have a low polydispersity [55] .
Mucoadhesive dendrimers could be used to increase the drug retention time on the ocular surface after topical administration, with the additional advantage that they do not provoke blurred vision or formation of any veil on the corneal region, problems typically associated with other bioadhesive polymers [56] . This idea was firstly explored by Vandamme and Brobeck [57] . They tested several families of polyamidoamine (PAMAM) dendrimers in combination with pilocarpine nitrate and tropicamide as model drugs (miotic and mydriatic activity, respectively) in New Zealand albino rabbits. No ocular irritation or reflex tearing was observed with any of the dendrimers evaluated (concentrations up to 2.0 % w/v), after instillation. The residence time of PAMAM dendrimers with amino surface groups was significantly longer than that of Carbopol® or HPMC solutions. During the evaluation of dendrimer-drug interactions, a host-guest relationship was suggested leading to sustained release of both drugs. The in vivo results obtained showed that the coadministration of PAMAM dendrimers with these drugs prolonged their pharmacological effect, indicating an increment in the precorneal residence time. This aspect was deeply evaluated by Bravo-Osuna et al. [58] . These authors developed the first in vitro method specifically designed to evaluate mucoadhesion with ocular mucins. The technique developed, based on biosensor chip technology, was able to evaluate the interfacial interaction phenomena between human transmembrane ocular mucins and dendrimers. A strong tendency to originate interfacial interaction with human ocular transmembrane mucins was observed for PAMAM dendrimers compared to classical polymers typically used to increase the drug retention time on the ocular surface (hyaluronic acid, carboxymethyl cellulose, and hydroxypropylmethyl cellulose), showing a relevant importance of the co-operative effect of dendrimer due to the proximity of the active chemical groups and the high importance of non-ionic interactions at that level. PAMAM-mucin interactions observed were statistically similar for PAMAM-NH 2 (generation 4; 2 %) and PAMAM-OH (generation 4; 2 %), although the latter can only develop weaker interactions, such as hydrogen bonds, with mucins.
Yao et al. evaluated the potential of PAMAM complexes with puerarin as corneal penetration enhancement agents using the Valia-Chien diffusion cell with excised rabbit corneas [59, 60] . The enhancing permeation behavior of PAMAM dendrimers was observed probably due to their interaction with corneal epithelium membrane cells or originated by their ability to relax the epithelium cell junctions to increase the drug flux. PAMAM dendrimers have also been explored as a gel-forming tool to increase the residence time of drugs or even other drug delivery systems on the ocular surface. Holden et al. prepared PAMAM-PEG cross-linked gels able to enhance the corneal transport of two antiglaucoma drugs (brimonidine and timolol maleate) up to 4.6-fold in comparison to drug solutions [61] . When these drugs were previously encapsulated in PLGA nanoparticles and suspended in PAMAM gels, the hypotensive effect was in vivo detected in the aqueous humor and cornea up to 7 days after instillation in Dutch-belted rabbits [62] .
Other dendrimers have been also tested at ocular topical level. Spataro et al. developed an interesting new series of phosphorus-containing dendrimers [63] . The dendrimers were used to form electrostatic complexes with carteolol, an ocular antihypertensive drug used to reduce the intraocular pressure in glaucoma treatment. Complexes were instilled in rabbits' eyes to evaluate the benefit of these nanosystems to enhance the penetration of the drug to the aqueous humor. The quantity of carteolol penetrating inside the eye was larger (2.5-fold) than expected when compared with carteolol alone. In another interesting work, Durairaj and co-workers evaluated the use of complexes formed by the combination of dendrimeric polyguanidilyated translocators (DPTs) and gatifloxacin in the treatment of bacterial conjunctivitis [64, 65] . The complexes formed nanostructures (346 nm). It was observed that the complexes rapidly penetrated into the corneal cell in a few minutes, in comparison to drug alone. The nanosized complex was instilled in the eye of New Zealand rabbits, showing an increment in the bioavailability of the drug in targeted tissues in conjunctiva and cornea, when compared with drug solution. Authors suggested that the systems created would allow the instillation of the drug in the complex only once a day to control the infection. Mishra and Jain also observed an increment in drug bioavailability after instillation in New Zealand rabbits of nanostructures formed by the combination of acetazolamide with G5 poly(propyleneimine) (PPI) dendrimers. The reduction of the intraocular pressure was sustained for almost 4 h for the dendrimer-based formulation, while the pharmacological effect was observed only up to 2 h when plain drug solution was used. Authors suggested that the interaction of dendrimer formulation with the corneal surface might form a structure that leads to the entrapment of higher amounts of the instilled dose [66] .
In situ gelling systems
In situ gelling systems are novel drug delivery approaches with the ability for sol-gel conversion upon change in physicochemical parameters. When applied in the eye, these viscous polymer-based solutions exhibit a sol-to-gel phase transition due to different biological stimuli (ionic strenght, temperature, or pH). The majority of the studies have been performed on ion-activated in situ gelling solutions which are able to form a gel after being in contact with the cations present in tears [67] . According to the studies reported by Rupenthal et al., formulations based on gellan gum and carrageenan exhibited the most favorable characteristics in terms of phase transition, rheological and textural properties, and reducing nasolacrimal drainage [68] . Delivery systems based on gellan gum and carrageenan were able to better retain an antisense oligodeoxynucleotide (AsODN) intended to improve wound healing on the ocular surface when compared to the uncharged hydroxypropylmethylcellulose formulation [69] .
Intraocular administration
Intraocular administration covers several routes that target the anterior and/or posterior segment of the eye, such as intracameral, intravitreal, or subretinal injections (Fig. 1) . Intraocular drug delivery refers to the release of the therapeutic agents into the eye, in some cases targeted directly at the site of action. In this way, drugs diffuse locally, reducing the delivery to other non-intended sites of action and the potential side effects produced [70, 71] .
Intracameral administration is exclusively used to describe the injection of formulations into the anterior segment of the eye. However, this route does not allow delivering significant concentrations of drugs to the posterior segment, so it is generally used to prevent endophthalmitis by delivering antibiotics after cataract surgery [72] . Care should be taken when injecting microparticles into the anterior chamber because they can cause physical clogging of the aqueous outflow increasing intraocular pressure [73] .
Intravitreal injection is the most efficient route to treat posterior segment disorders. In comparison to topical and systemic administrations, this route presents clear advantages, assuring a very low prevalence of systemic side effects. However, a number of disadvantages are associated with the intravitreal administration. First of all, it is an invasive route that breaks the ocular tissues compromising the immunity privilege of the eye. Furthermore, as the drug is locally deposited, due to the initial high concentrations that are achieved after the injection, retinal toxicity can be produced. Although the clearance from the vitreous depends on the lipophilicity and molecular weight of the active substance, this process is usually fast. In several cases, drug elimination occurs in a few hours. Moreover, due to the fact that most of the posterior segment diseases are chronic, repeated injections are needed even for active substances presenting long half-life values. Besides, frequent repeated injections increase the risk of endophthalmitis, damage to the lens, or retinal detachment, among others. Thus, the general objective in the development of new intraocular therapies for chronic diseases is to maintain drug concentrations within the therapeutic window at the target site and reduce the frequency of administration [70] . In order to reach these objectives, several authors have explored the use of microscale and nanoscale systems for the treatment of posterior segment diseases [71] . Microsystems have demonstrated to be useful tools in long-term therapies. They can control the release of the active substance for weeks, even months, reducing the frequency of injections and maintaining sustained drug concentrations in the vitreous [74] . The utility of nanosystems for the treatment of posterior segment diseases is more directed to gene delivery and to the protection of the active substances from the external environment to be targeted to damage ocular tissues. This strategy is especially important when bioengineered compounds are used, such as peptides, proteins, or nucleic acids [75, 76] .
The usefulness of subretinal injections to treat alterations in the retina is clear; however, the risk of this administration is evident and is still being tested in the preclinical setting [77] .
Microparticles
The main advantage with the use of microparticles for intraocular administrations is that they can be injected in the form of suspensions by using conventional needles. Microparticles are typically dispersed in a physiological vehicle (phosphate buffer or balanced salt solutions), but sometimes viscous vehicles, such as hyaluronic acid or hydroxypropylmethyl cellulose, are used to improve the injectability of the suspensions [78] .
Many authors have tested the use of microparticles as drug carriers over the last decades. Posterior segment diseases such as proliferative vitreoretinopathy, age-related macular degeneration, diabetic retinopathy, uveitis, macular edema, cytomegalovirus, glaucoma, and retinitis pigmentosa have been treated with drug-loaded microspheres with a relatively high rate of success [79] . For intraocular administration, a large variety of active substances have been included in microspheres (i.e., antiproliferatives, antiinflammatories, immunosuppressants, antibiotics, and even biotechnological therapeutic agents). Microparticulate systems have been prepared from biodegradable polymers such as gelatin, albumin, polyorthoesters, polyanhydrides, and polyesters. Among them, the PLA and poly(glycolic) acid (PGA) polymers and their co-polymers PLGA are the most employed. The use of these biomaterials in clinical practice has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). For ocular application, and especially for the treatment of diseases affecting the back of the eye, these erodible polymers have been employed to prepare different devices (implants, scleral plugs, pellets, discs, films, rods, nanoparticles, and microparticles) [80] .
An interesting work from Moritera et al. showed the administration of adryamicin-loaded microspheres (50 μm particle size) in an animal model of proliferative vitreoretinopathy. Authors found not only that the retinal detachment was decreased from 50 to 10 % in the rabbits after 4 weeks of the intravitreal injection but also that a significant decrease in the retinal toxicity was produced, when comparing a single injection of microspheres with the administration of the same amount of drug in solution [81, 82] . The antiviral effect of ganciclovir-loaded microspheres was evaluated by Veloso et al. in infected rabbits' eyes [71] . In treated eyes, vitritis, retinitis, and optic neuritis decreased during the 14 days of the study, in contrast to control eyes. Histopathology analysis showed minimal focal disruption of the retinal architecture in eyes injected with drug-loaded microspheres. After 8 weeks, no adverse tissue reaction was clinically or histopathologically observed in the injected eyes. Conti et al. developed PLA and PLGA microparticles loaded with acyclovir using the spraydrying technique. After 14 days, the active substance was detected in the vitreous of rabbits receiving D,L-PLA (28,000 g/ mol) microparticles (0.5 mg) [83] . Duvvuri et al. dispersed ganciclovir-loaded microspheres in a thermogellin PLGA-PEG-PLGA solution that was then injected in rabbit eyes. After the injection, drug levels in the vitreous were significantly higher and maintained for a prolonged time in comparison with a drug solution (14 days versus 54 h, respectively) [84] .
The treatment of intraocular inflammation, uveitis, or intraocular immune disorders with microparticles has also been extensively investigated. Cyclosporine-loaded PLGA 75:25 microparticles (50 μm particle size) prepared by He et al. [85] produced a ten-times increment in the residence time of the drug in comparison with a cyclosporine A solution. Microspheres were also able to maintain therapeutic concentrations for at least 65 days in the disease-related tissues such as the choroid-retina and iris-cilliary body. Dexamethasoneloaded PLGA 50:50 microspheres (53 μm) have been tested for the prevention of ocular inflammation in an animal model of uveitis provoked by lipopolysaccharide injection [86] . Authors showed that the intraocular inflammation was significantly reduced in animals receiving drug-loaded microspheres in comparison to control (blank microspheres), even when secondary uveitis was simulated with a second injection of lipopolysaccharide 30 days after microspheres injection.
Some studies performed with microspheres loaded with anti-inflammatory drugs have already been performed in humans. For example, Cardillo and co-workers [87] reported human studies of the intravitreal injection of triamcinoloneloaded PLGA microspheres. Nine volunteer patients suffering from diffuse macular edema were treated with the microspheres, and the efficacy of the formulation was compared to conventional triamcinolone injections. Interestingly, the eyes treated with triamcinolone microspheres showed a marked decrease in retinal thickness as well as an improved visual acuity for about 12 months.
The development of new bioengineered products such as peptides, proteins, or nucleic acids for the treatment of ophthalmic diseases has made it necessary to design new microparticulate systems able to effectively administrate such molecules to the target site. This strategy has been employed for the treatment of glaucoma. The therapeutic approach focuses on promoting the survival of retinal ganglion cells (RGCs). In that sense, Andrieu-Soler et al. [88] developed PLGA microspheres loaded with GDNF, a glial-cell-linederived neurothropic factor, which was efficient in preventing the retinal degeneration in a retinosis (rd1) mouse model for 17 days. The efficacy of GDNF-loaded microspheres has also been tested in a glaucoma rat model based on the intraocular pressure elevation with an episcleral injection of a hypertonic NaCl solution, showing a significant increase of the survival of retinal ganglion cells and their axons 9 weeks after the intravitreal injection of the microspheres [89] . ChecaCasalengua et al. [74] developed PLGA microparticles (20-40 μm) loaded with an antioxidant (vitamin E) and GDNF. The multiloaded microparticulate systems were able to release the protein in its bioactive form for more than 130 days. Afterwards, authors observed that a single injection of these microspheres (25 μg) in a rat model of glaucoma based on intraocular pressure elevation was sufficient to promote a retinal ganglion cell's survival of 72.7 % 11 weeks after injection, in contrast to 36.6, 30.6, and 29.0 % of RGC survival observed in eyes treated with GDNF in solution, vitamin E, and blank microspheres, respectively.
Andrieu-Soler et al. also studied the efficacy of PLGA microspheres (27 μm) loaded with recombinant human glial cell line-derived neurotrophic factor (rhGDNF) in preventing retinal degeneration in an animal model (mice) of rd1 for 17 days [85] . Authors described a significant delay of rod photoreceptor degeneration in the animals receiving the rhGDNF-loaded microspheres in comparison to the control group (untreated animals) or the group receiving blank microspheres. Retrobulbar administration of PLGA microspheres loaded with the IKK2 inhibitor, 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide (TPCA-1), promoted a significant reduction of laser-induced choroidal neovascularization (CNV). The effects were observed 7 days after laser injury in mice. The authors suggested a potential clinical interest of the TPCA-1 microparticulate system in the treatment of CNV in patients with wet age-related macular degeneration and other retinal neovascularization pathologies [90] . PLGA microspheres prepared by electrospray for the release of ranibizumab by intraocular administration have been reported by Zhang et al. The proposed encapsulation method provided minimal loss of bioactivity of the antivascular endothelial growth factor. After intravitreal injection of the microparticles in a chick model, the active molecule was released in a controlled fashion for over 1 month. Interestingly, no significant reaction or cell death was observed after intravitreal injection of 0.2 mg of particles [91] .
The utility of microparticles in rare ocular diseases, such as retinitis pigmentosa, has also been evaluated. PLGA microspheres (2-40 μm) loaded with tauroursodeoxycholic acid (TUDCA) and phosphate solution (control) were intravitreally injected in homozygous P23H line 20-day-old rats. After assessing higher retinal functionality at different postnatal days (P80, P100, and P120) in the TUDCA-treated animals, the authors suggested the potential of these formulations to delay vision loss in retinitis pigmentosa [92] .
Nanoparticles
Advances have already been performed in the intravitreal and subretinal administration of nanoparticles. Robinson et al. evaluated the efficacy of AG1478-loaded PLGA nanoparticles (359 ± 54 nm) by intravitreal injections in a rat optic nerve crush injury model [75] . Four weeks after the injection, authors were able to detect NPs in the vitreous and could find fiber growth through the injury site. In a different study, the molecule tetra-iodothyroacetic acid, able to block angiogenic action over VEGF and erythropoietin, was encapsulated in PLGA nanoparticles, and its effect was evaluated in mice. While the administration of the drug alone had no statistically significant effect on retinal neovascularization compared with the vehicle, the administration of a single injection of loaded NPs significantly reduced retinal neovascularization by 30.9 % 3 days after injection [76] . An expression plasmid of plasminogen kringle (K5), a natural angiogenic inhibitor, was encapsulated in PLGA/chitosan NPs (260 ± 30 nm) and injected into the vitreous in rats. Results showed that, for at least 4 weeks, K5-NPs attenuated vascular endothelial growth factor and reduced leukostasis and vascular leakage in the rat model used [93] . Farjo et al. determined the efficiency of compacted DNA nanoparticles to transfer a plasmid encoding the green fluorescent protein (EGFP). Nanoparticles were administered by subretinal injection (1 μL) in mice. Two days post-injection in the the examination, a fluorescent signal in the retina inner plexiform layer and in retinal ganglion cells was detected. Substantial EGF fluorescence was also detected in the lens, cornea, and trabecular meshwork with no evidence of cellular infiltration or inflammation [94] . Other authors studied the therapeutic efficacy and safety of compacted DNA-NP gene delivery into the subretinal space of a juvenile mouse model of retinitis pigmentosa. Electroretinography studies showed a modest but statistically significant improvement in rod function in comparison to controls after the injections [77] . Cai et al. determined the utility of small nanoparticles (diameter <8 nm) composed of a therapeutic gene in a mouse model of retinitis pigmentosa with a phenotype of slow retinal degeneration. In this work, NPs were compacted by a peptide with a high transfection activity (CK30PEG, a PEG substituted 30-mer lysine peptide). The efficacy of the system was evaluated in terms of its ability to rescue the disease phenotype in the animal model, measuring the levels of several photoreceptor-specific proteins typically reduced in these animals. Nearly all of the photoreceptor populations were transfected by the subretinal delivery of nanoparticles. Additionally, a cone function restoration to almost normal levels and a rod function improvement were observed in treated animals in comparison to control [95] . Mitra et al. formulated, characterized, and tested glycol-chitosan nanoparticles for gene delivery to the eye [96] . pscCBA-GFPA (pDNA), known to express green fluorescent protein (GFP), was compacted with glycol-chitosan nanoparticles. In order to assess the ability of nanoparticles to drive ocular gene expression in vivo, particles were subretinally injected in wild-type albino mice. Authors observed GFP expression in nanoparticles but not pDNA alone. GFP expression was primarily localized to the region of injection. This study showed that the pDNA was stable inside the non-viral system and retained its native conformation and functional integrity, facilitating gene expression in the retinal pigment epithelium after subretinal delivery.
Chen et al. [97] studied the ability of intravitreally injected connexin43 mimetic peptide (Cx43 MP) encapsulated in PLGA microparticles (9 μm) and nanoparticles (113 nm) to promote retinal ganglion cell survival in a retinal ischaemiareperfusion rat model. The entrapment efficiencies resulted 70 % for nanoparticles and 97 % for microparticles with 100 % release achieved in 63 days for nanoparticles and 112 days for the microparticles. In the acute injury model, nanoparticles provided sufficient high Cx43 MP concentrations at the initial stage. Although microparticles exhibited longer sustained release of the active substance in vitro, the initial Cx43 MP concentration available may have been insufficient to downregulate the initial inflammatory response.
Liposomes
As well as nanoparticulate systems, liposomal formulations in intraocular drug delivery are intended to target and protect the active substance and improve the therapeutic effect. Liposomes are able to improve drug stability in biologic fluids and can reduce retinal toxicity [98] . However, they have limited drug capacity and are difficult to sterilize, making it difficult to develop liposomal formulations for intraocular drug delivery.
Several drugs with known high toxicity have been successfully formulated as liposomal formulations. A clear example is amphotericin B, which produced less toxic effects than a marketed solution after a single intravitreal injection in healthy pigmented rabbits [99, 100] . In a different study, an acyclovir pro-drug called HDP-P-GCV was entrapped into liposomes and injected into the vitreous in an animal model of cytomegalovirus retinitis, being able to protect the treated eyes against the virus for 4-6 weeks [101] .
Several authors have evaluated the efficacy of liposomes to encapsulate DNA or RNA for gene therapy. However, these lipoplexes have to overcome two important limitations. Firstly, the vitreous is a high-viscosity material that induces lipoplex aggregation and is able to hinder the diffusion of lipoplexes to the site of action. Secondly, the presence of the polyanionic glycoaminoglycans in the vitreous can displace the DNA from the complex. In order to minimize these limitations, Peeters et al. developed PEGylated lipoplexes (1,2-distearoyl-sn-glycero-3 phosphatidylethanolamine-PEG) that showed a decreased surface charge in comparison to nonPEGylated lipoplexes and an increased transport to the retinal pigment epithelium [102] . Bochot et al. also developed PEGylated liposomes for the intravitreal delivery of an oligonucleotide model, pdT16. The liposomal formulation (PC:Cht:PEG-Polyethylene glycol-distearoyl ethyl phosphocoline) was able to protect the active substance against degradation in the vitreous and prolonged the pdT16 release into the vitreous, retina, and choroid [103] . Lajavardi et al. also used PEGylated liposomes to improve intravitreal delivery of a proteic substance, vasointestinal peptide (VIP), for the treatment of uveitis. Labeled rhodamine (Rh) liposomes (PC:PG:Cht:PEG-Polyethylene glycol-distearoyl ethyl phosphocoline:PE-Rh) dispersed in hyaluronic acid 1.2 % were able to protect the protein from degradation in the vitreous and to maintain a sustained release of VIP [104] .
The potential of liposomes to deliver functional proteins to retinal photoreceptors and modulate their physiological response has recently been investigated by Asteriti et al. Vesicles, prepared with L-α-phosphatidylcholine and cholesterol (8:10), were loaded with rhodamine B, recombinant myristoylated recoverin (an endogenous protein regulating the duration of the phototransduction cascade in photoreceptor cells), or antibodies against recoverin [105] . The efficacy of liposomes was tested in isolated mouse retinas by electrophysiology. The in vivo retinal biodistribution was evaluated by intravitreal injection (1 μL) in mice. Electrophysiological experiments showed that the temperature seemed to be an important factor influencing the fusion of the vesicles with membranes. If the experiment was performed at 22°C, no significant differences between treated and untreated retinas could be noticed, while a modification to the phototransduction cascade was produced when the experiment was performed at body temperature, due to a fusion of the vesicle within the photoreceptor layer.
Dendrimers
Intravitreal injection of drug delivery systems based on dendrimers has been explored in several works. Wimmer et al. prepared lipid-Lys dendrimers able to promote the ODN-1 (anti-VEGF activity) delivery into the nuclei of retinal pigmented epithelium cell (RPE D407) cultures [106] . These new dendritic structures combined the presence of the lipidic part, which might facilitate their crossing of biological membranes, and the poly-Lys part that could interact with ODN-1 protecting it against nucleases. The chemical family of these lipid-Lys dendrimers was subsequently increased, and their utility in vivo was evaluated showing a reduction in VEGF expression (40-60 % during the first 24 h) after intravitreal injection in choroidal neovascularisation animal models (rats) [107] . Interestingly, some of the prototypes evaluated extended the antiangiogenic effect up to 4 months. No significant toxicity and damage were observed on injected rat eyes after ophthalmological examinations [108] . The presence of galactose moieties in the lipid-Lys dendrimer structure increased their solubility and their transfection efficiency in RPE 51 cells [109] .
Iezzi et al. demonstrated that the combination of PAMAM-OH dendrimers with fluocinolone acetonide was able to release the drug in a sustained manner for 90 days. In vivo efficacy studies demonstrated that only one intravitreal injection (1 μg of drug/7 μg of dendrimer) was able to stop retinal degeneration, preserve photoreceptor outer nuclear cell counts, and attenuate activated microglia, for an entire month in a rat retinal degeneration model. According to authors, this pathology-dependent biodistribution could be exploited to treat disease promoting retinal neuroinflammation such as age-related macular degeneration and retinitis pigmentosa [110] . In this sense, other authors have also explored the use of PAMAM-OH dendrimers for the intracellular delivery of anti-inflammatory drugs at retinal level. Kambhampati et al. evaluated the in vitro cell uptake of triamcinolone acetonide conjugated with PAMAM-OH dendrimers in microglial and retinal pigmented epithelium [111] . The nanosystems created were able to reduce the inflammatory activity in microglia cells for 3 days after a 12-h treatment. Conjugated dendrimers also promoted a reduction in VEGF production in hypoxic RPE cells 100-fold higher than the same amount of drug alone. Authors suggested that the combination of the drug with the dendrimer not only improved its therapeutic effect but also reduced its toxicity. They postulated these conjugates as a useful strategy in the treatment of ocular diseases characterized by neuroinflammation and neovascularization such as age-related macular degeneration or diabetic retinopathy among others. Hennig et al. prepared PEGylated PAMAM dendrimers conjugated with angiotensin receptor blockers, demonstrating that this combination increased the receptor affinity 6-fold [112] . This fact could be also interesting in the treatment of ocular diseases accompanied by retinal neovascularization; however, to our knowledge, no in vivo studies have been performed in this sense so far.
Periocular and suprachoroidal administration
Periocular administration involves peribulbar, posterior juxtascleral, retrobulbar, sub-tenon, and subconjunctival routes (Fig. 1) . Depending on the site of administration, a drug can access target sites in the posterior segment through the sclera, the choroid and/or aqueous humor, and vitreous. However, the lymphatic flow in conjunctiva and episclera and/or the blood flow of conjunctiva and choroid eliminate the drug very fast from the administration site, limiting the access of these molecules to the intraocular tissues, even if they are macromolecules [113] [114] [115] . Periocular administration is a less invasive and potentially safer alternative than intraocular injections, and the interest of this route is mainly directed to the anterior segment of the eye (anti-inflammatory agents and anesthetics by subconjunctival injection) [116] . Another type of drug administration is the suprachoroidal route, whose usefulness has recently been demonstrated in the delivery of active substances to the back of the eye [117] .
Microparticles
In order to provide sustained drug levels and enhanced drug absorption into the intraocular tissues, periocularly administered microparticles have to be maintained at the site of administration for a long time. However, the particle size may limit the therapeutic effectiveness of these systems, by influencing their clearance by the systemic and lymphatic circulation. In this context, Amrite et al. studied the effect of the particle size disposition of non-biodegradable nanoparticles (20 and 200 nm) and microparticles (2 μm). In that study, only 200-nm and 2-μm particles stayed at the site of administration for at least 60 days, while 20-nm particles were rapidly cleared [118, 119] . Kompella et al. studied the delivery of antiinflammatory drugs from microparticles and nanoparticles by periocular administration. Budesonide-loaded PLA particles (345-nm and 3.60-μ m particle si zes) were subconjunctivally injected in rats, and the ocular tissue levels of the drug were analyzed at different times in retina, vitreous, lens, and cornea. On day 1, drug levels in the nanoparticle group were higher in all the tissues that were evaluated, when results were compared with the group receiving microparticles. However, the opposite situation took place on days 7 and 14, showing the potential utility on biodegradable microparticles in sustained retinal drug delivery [120] . Ayalasomayajula et al. studied the potential usefulness of subconjunctival injections of celecoxib-loaded PLGA 85:15 microparticles (3.9 μm) in the treatment of diabetes-induced retinal abnormalities. In a rat model of diabetes-induced retinal oxidative stress, microparticles were able to release the drug in a sustained manner during 14 days in retina, vitreous, lens, and cornea. Furthermore, diabetes-induced inflammation was significantly reduced [121] . In a different work, celecoxib-loaded microparticles were able to delay the development or progression of the early pathopysiological changes in the retina in a streptozotocin diabetic rat model. Celecoxib microparticles significantly reduced the diabetes-induced elevations of prostaglandin E2 (PGE2) secretion, VEGF, the vitreous-plasma protein ratio, and the blood-retinal barrier leakage without causing any damage to the retina [122] .
The effect of the subconjuntival injection of adriamycinloaded PLA microspheres in the prevention of post-surgical fibrosis after glaucoma filtration surgery was evaluated by Kimura et al. The results showed an improvement in intraocular pressure reduction and filtering bleb survival in the treated eye in comparison to the control eyes, up to 12 days after the injection [123] . Gomes do Santos et al. prepared nanosized complexes of antisense TGF-β2 phosphorothioate oligonucleotides (PS-ODN) with and without polyethylenimine (PEI) encapsulated in PLGA microspheres (BTrojan^micro-spheres) to be injected in a rabbit experimental model of glaucoma surgery. Results showed a significant increase in the intracellular penetration of ODN in conjunctival cells and demonstrated a 100 % bleb survival. The subconjunctival injection prevented post-surgical fibrosis following trabeculectomy for 42 days [124] .
The utility of PLGA/glucose microspheres loaded with PKC412 has also been evaluated by Saishin et al. in a porcine model of laser-induced choroidal neovascularization. The subconjunctival injection of these particles caused a significant suppression of the neovascularization development at rupture sites in Bruch's membrane, and, 20 days after injection, drug levels were detectable in vitreous, retina, and choroid, indicating the penetration of the drug across different tissues [125] . In this context, a different approach studied the use of anti-VEGF RNA aptamer-loaded PLGA microspheres [126] . The microparticles were able to deliver the aptamer in a sustained manner and the released aptamer retained its bioactivity, according to its antiangiogenic effect in human umbilical vein endothelial cells. After an in vitro permeation study, it was observed that microparticles were able to release the aptamer through the sclera for a 6-day period.
Not only subconjunctival but also other periocular routes have been evaluated. Interesting results have been obtained by administering drug-loaded microparticles in the sub-tenon virtual space. Panganelli et al. demonstrated the utility of the subtenon injection of ciprofloxacin-loaded microspheres combined with triamcinolone in the prevention of the ocular inflammation and infection after cataract surgery. Authors compared this treatment with the topical administration of prednisolone (1 %) and ciprofloxacin (3 %) eye drops during 28 days. Both treatments were evaluated in terms of efficacy (anterior chamber cell and flare, conjunctival erythema, ciliary flush, or symptoms of ocular inflammation) and safety (intraocular pressure, biomicroscopy, and ophthalmoscopic findings). Results demonstrated that a single periocular injection had the same therapeutic response and ocular tolerance as continuous administration of eye drops in controlling inflammations after cataract surgery [127] .
The tolerance of fluorescent nanoparticles (20 and 500 nm) and microspheres (1 and 10 mm) after suprachoroidal administration was studied by Patel et al. Authors described a normal fundus of the injected rabbit eyes with no inflammation or abnormalities as compared with uninjected eyes [128] . An interesting study tested the localization of microparticles and nanoparticles at the site of injection after administration into the suprachoroidal space using microneedles [129] . To this, non-biodegradable fluorescent particles were deposited in the suprachoroidal space using different solutions. When suspended in saline solutions, the particles were distributed over 29-42 % of the suprachoroidal space. The larger spreading (100 %) was observed for moderately non-Newtonian vehicles. Particles were localized at the site of injection for strong non-Newtonian polymer solutions.
The combination of silicon microparticles with electrospun polycaprolactone (PCL) fibers was designed to support mammalian cells providing a substantial surface area of efficient delivery of adsorbed active substances. In this novel implantable scaffold, particles of different sizes (150-250 or <40 μm) were pressed into the fibers made by PCL. After implantation under the conjunctiva, the selected formulation did not produce significant neovascularization but promoted a macrophage and mild foreign body response [130] .
Nanoparticles
As mentioned previously, the therapeutic utility of periocularly administered nanoparticles is limited by their size. Only particle sizes larger than 200 nm are able to remain in the administration site [119, 131] .
Kompella et al. evaluated the effect of subconjunctivally administered budesonide-loaded PLA nanoparticles (345 nm) in Sprague Dawley rats. The effect of the system was compared with a single injection of a budesonide solution, and drug levels in retina and other tissues were determined at 1, 3, 7, and 14 days post-injection. At the end of day 7, budesonide concentration in cornea and vitreous was higher in the group treated with nanoparticles than in controls. However, on day 14, drug levels were below limits of detection for both solution and budesonide NP groups in all the tissues analyzed [120] .
Kalita et al. carried out a preliminary study to examine the safety of a single posterior sub-tenon injection of 1 mL (10 mg/ mL) of carboplatin-loaded polymethylmethacrilate nanoparticles prepared by free-radical emulsion polymerization of methyl methacrylate from an aqueous solution containing carboplatin (110 ± 10 nm, polydispersity index 0.2, negatively charged) for the treatment of advanced retinoblastoma in humans [132] . Six patients were randomly distributed to receive a fixed dose of 10-mg/mL posterior sub-tenon injection of freshly prepared nanoparticle suspension at 6, 24, or 72 h prior to enucleation. The level of carboplatin was analyzed in ocular tissues, and eyes were evaluated for evidence of choroidal and retinal toxic effects. Authors concluded that nanoparticulate forms of carboplatin may provide facilitated delivery across sclera to the intraocular target, without associated short-term tissue and systemic side effects in humans. However, they claimed that a larger clinical trial in humans was needed to assess clinical efficacy and long-term toxicity.
Feng et al. [133] evaluated the ocular distribution of alexa647-labeled pRNA nanoparticles, pRNA-3WJ (BY^shape) and pRNA-X (BX^shape) after subconjunctival injection in female mice and their feasibility to deliver the nanoparticles (8-12 nm) to corneal and retinal cells. They performed imaging studies in the whole-body and dissected ocular tissues and studied the distribution and clearance of the nanoparticles by monitoring the eyes in vivo. Both pRNA-X and p-RNA3WJ were found in conjunctiva, cornea, and scleral cells after the injection. However, only pRNA-X was found in the retina. Authors suggested that this situation was probably related to the sizes and shapes of the nanoparticles. They also noticed an important clearance of the systems through the cervical lymph node.
Liposomes
Interestingly, liposomal nanocarriers have been used as novel systems for vaccine delivery at periocular level. In this sense, Cortesi et al. [134] have demonstrated the main role of periocular vaccination for preventing HSV infection in rabbits. Authors developed liposomes composed of PC:Cht:Dioctadecyl-dimethyl-ammonium bromide and a recombinant secreted form HSV-1 glycoprotein B(gB1s) with a protective immunity activity and two peptides mimicking gB1s, DTK1, and DTK2, with additional antiherpetic activity (300 nm; +23 mV). Rabbits were given a subconjunctival vaccination three times at 3-week intervals. Then, they were infected with a pathogenic HSV-1 variant and clinical eye signs and symptoms (conjunctivitis, iritis, epithelial keratitis, and corneal clouding) were evaluated on days 3, 5, 7, 10, and 14 post-infection. Six out of nine animals treated survived in comparison with controls (animals vaccinated with unloaded liposomes in which 0/9 animals survived). These results support the concept that local periocular vaccination can be potentially used as a successful therapeutic vaccine against recurrent HSV-1 ocular shedding [135] . Elsaid et al. prepared and characterized sirolimus-loaded nanocarriers using cholesterol-poly(ethylene) glycol polymers (Cht-PEG, 1000 or 5000 g/mol) to assess their effect on transcleral permeation and drug retention [136] . The particle size ranged from 11.7 to 16.2 nm with a narrow particle size distribution. The permeability and diffusion coefficients did not vary significantly between Cht-PEG polymers, being 14-fold lower than the drug dissolved in organic solvents such as dimethyl sulfoxide or methanol, known to enhance ocular permeation. The scleral drug retention was 13-28-fold higher than that of the diluted sirolimus solution. Formulations showed a good stability, with little change in the size of the nanocarriers over time, and a good drug loading and entrapment efficiency (77-82 %). Negatively charged Cht-PEG 5000 g/mol had lower scleral drug retention than the neutral Cht-PEG 1000 g/mol, although both showed successful transcleral drug retention and permeation. According to the authors, results suggested that Cht-PEG nanocarriers are potential tools for the delivery of lipophilic drugs to the anterior or posterior segments of the eye.
Dendrimers
Dendrimers have been also explored in the peroicular route. Shaunak et al. conjugated PAMAM dendrimers and glucosamine or glucosamine 6-sulfate to obtain immuno-modulator systems or antiangiogenic systems respectively. The conjugates were subconjunctivaly co-administered in a rabbit model of wound healing after glaucoma filtration surgery showing an increment of the long-term success of the surgery from 30 to 80 %, and also a reduction in both inflammation and angiogenic responses. Furthermore, the protection was observed 30 days post-injection [137] .
Kang et al. [138] prepared nanoparticles (258 nm) by aggregation of host-guest PAMAM-carboplatin systems. These nanoparticles were administered in retinoblastoma animal models (LHβ-Tag mice) by subconjunctival injection. The mean tumor mass in eyes was significantly reduced after injection of the dendrimeric systems in comparison to the nontreated group and also in comparison to the group treated with carboplastin aqueous solution due to the prolonged retention of nanoparticles and the sustained drug delivery.
Potential clinical translation
The treatment of ophthalmic diseases requires the development of systems designed to deliver the active agent close to the target tissues. Depending on the site of administration, different types of devices such as implants and microsystems or nanosystems have been developed. The topical route of administration is preferred when the site of action is the ocular surface or the anterior segment of the eye. On the contrary, if the active substance has to reach the posterior segment of the eye, intravitreal administration is more adequated, targeting the drug directly to its site of action.
Among the sustained-release products proposed in ophthalmology for the treatment of diseases of the back of the eye, there are several implants in clinical practice (Table 1) . Depending on the polymer employed, they can be biodegradable or non-biodegradable. The main advantage of these devices is that the delivery of the drug occurs over a long period of time. However, a drawback of the non-biodegradable systems is that they remain inside the eye or have to be surgically removed.
Biodegradable microparticles are emerging tools to treat chronic diseases affecting the posterior segment of the eye. These novel formulations are able to release the active substance over long periods of time compared to nanoparticles. As cited previously, microsized particles can contain different POAG primary open angle glaucoma, OH ocular hypertension, DME diabetic macular edema, MMP mucus penetrating particle technology active substances in the same device resulting useful in the treatment of multifactorial diseases. The tolerance of microparticles intended for the treatment of posterior segment diseases is a critical issue as the retina and surrounding tissues are essential for clear vision. Polymers employed must present good tolerance with the intraocular tissues. Furthermore, it is important to assure that particles aggregate outside the path of vision after being injected, avoiding the interference with vision [87] . The aggregation phenomena would promote a slow delivery of the drug extending the therapeutic effect, although this fact has to be studied through pharmacokinetic studies.
In spite of the clear advantages of using nanoparticles, their clinical translation is still limited. Their use for topical administration has several drawbacks, derived from the tolerance and the penetration ability of the particles across the ocular tissues [1] . However, they clearly provide beneficial effects such as enhancement of drug bioavailability [147] . Nevertheless, repeated administration can potentially cause accumulation of particles resulting in damage of the tissue if the rate of the nanosystem biodegradation is lower than the interval dosing. Unfortunately, studies including repeated administrations are not reported in the literature. Furthermore, special attention must be paid to the tolerability of the formulation, mainly if they are destined to treat chronic diseases. In fact, there are a number of interesting nanosystems under investigation however with low possibilities to reach the clinic because of their associated toxicity. For this reason, it is very important to assure elimination as well as a high tolerance of the nanosized formulations. Theoretically, this can be done by the use of non-toxic biodegradable materials. Nanoparticles, liposomes, niosomes, and dendrimers also present great interest in gene therapy to protect the active substance improving the therapeutic effect [94, 96, 103, 107, 108] . For the back of the eye, the diffusion of the nanosized systems throughout the vitreous to the target cells after their injection is a critical issue which warrants further investigation [102] .
Hybrid formulations composed of nanoparticles, liposomes, or niosomes combined with polymeric solutions have been explored with good results in terms of tolerance and efficacy [16, 18, 19, 31, 33-37, 41, 43, 49, 148] . From a technological point of view, the increase of the viscosity thanks to the use of these polymeric solutions improves the stability of the formulation [37, 147] . Also, the combination of polymers employed in clinical practice, for the treatment of ocular surface conditions with nanosystems loaded with active substances, is a promising therapeutic tool in chronic therapies as it is the case of glaucoma. Chronic treatment of glaucoma with hypotensive agents includes the administration of one drop/day for long periods of time. This therapy is associated with changes to the corneal surface that can be diminished thanks to the use of the previous mentioned formulations. From a clinical point of view, hybrid formulations of nanovesicles with polymers employed for dry eye treatment would result in especially interesting long-term treatments and could contribute to patient adherence to treatment. The combination of nanosystems and microsystems is also a very interesting tool for the treatment of diseases in the posterior segment of the eye as it combines the benefit of both systems [149] .
In summary, the right choice of the ophthalmic drug delivery system depends on the ophthalmic disease, the ocular target site, and the route of administration.
The translation of these technological approaches is already evident in clinical practice. In fact, some systems based on liposomes and microemulsions have been able to reach the market (Table 1) as new platforms to treat ocular diseases, as drug delivery systems, or even as non-loaded vehicles. For example, a marketed formulation based on liposomes is currently being prescribed for the treatment for dry eye (Tears Again, Optima Pharmaceutical, GmbH, Germany). This non-loaded formulation is applied directly to the eyelids with the eyes closed. Once administered, liposomes are able to migrate from the site of administration to the ocular surface. Another example is the positively charged emulsion Cationorm® multiophthalmic (Santen, UK Limited, St Albans, UK), indicated to moisten, lubricate, and protect the eye surface. Also, for the treatment of dry eye, the castor oil emulsion Restasis (0.05 % cyclosporine ophthalmic emulsion; Allergan, Irvine, EEUU) was the only marketed cyclosporineloaded ophthalmic formulation for several years until Ikervis®, a cyclosporine A formulation based on the Cationorm® microemulsion, was launched (1 mg/mL cyclosporine; Santen, UK Limited, St Albans, UK), licensed for the treatment of severe keratitis in adult patients with dry eye disease. Furthermore, according to the great number of clinical trials under development in the recent years (Table 2) , it is logical to expect an important increment of marketed new formulations based on these technologies in the near future.
